Private Advisor Group LLC Cuts Holdings in Moderna, Inc. (NASDAQ:MRNA)

Private Advisor Group LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 23,980 shares of the company’s stock after selling 474 shares during the period. Private Advisor Group LLC’s holdings in Moderna were worth $997,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. State Street Corp raised its position in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares in the last quarter. Wellington Management Group LLP lifted its position in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after buying an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after buying an additional 178,939 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $30.96 on Friday. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The stock has a market capitalization of $11.91 billion, a P/E ratio of -3.34 and a beta of 1.59. The company’s 50-day moving average is $37.47 and its 200 day moving average is $51.47.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of recent research reports. Leerink Partners lowered their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Wolfe Research initiated coverage on Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Finally, Evercore ISI set a $50.00 price target on Moderna in a research report on Friday, February 14th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average price target of $60.63.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.